Alpha Tau Medical shares surge 27.90% after-hours as first patient treated in Alpha DaRT glioblastoma pilot study.

Alpha Tau Medical surged 27.90% in after-hours trading following the announcement that the first patient was successfully treated using its Alpha DaRT® technology for recurrent glioblastoma in a pilot study. The trial, conducted at The Ohio State University, marks a critical milestone in advancing the company’s alpha-radiation therapy, which targets tumors with minimal damage to surrounding tissue. The treatment achieved over 95% tumor coverage and aligns with the FDA’s Breakthrough Device Designation, accelerating regulatory pathways. The news underscores progress in addressing a high-unmet-need cancer with limited treatment options, bolstering investor confidence in the technology’s potential. The pilot study’s focus on feasibility and safety, coupled with the innovative delivery method, highlights Alpha Tau’s strategic push to commercialize Alpha DaRT® for neuro-oncology applications.